Teva Pharmaceuticals
TEVA
533 hedge funds and large institutions have $9.88B invested in Teva Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 86 funds opening new positions, 190 increasing their positions, 154 reducing their positions, and 25 closing their positions.
364% more call options, than puts
Call options by funds: $577M | Put options by funds: $124M
244% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 25
23% more repeat investments, than reductions
Existing positions increased: 190 | Existing positions reduced: 154
23% more capital invested
Capital invested by funds: $8.05B → $9.88B (+$1.83B)
11% more funds holding
Funds holding: 481 → 533 (+52)
4% more funds holding in top 10
Funds holding in top 10: 24 → 25 (+1)
2.76% more ownership
Funds ownership: 50.92% → 53.68% (+2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$319M |
| 2 |
Morgan Stanley
New York
|
+$119M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$70.4M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$69.9M |
| 5 |
PC
PointState Capital
New York
|
+$62.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$141M |
| 2 |
SPC
Slate Path Capital
New York
|
-$103M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$51.5M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$44.7M |
| 5 |
Citigroup
New York
|
-$41.3M |
TEVA Hedge Fund Activity: Q2 2024 in Review
533 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2024, worth a combined $9.88B — up 23% from $8.05B a quarter earlier.
Buyers outnumbered sellers: 86 funds opened new TEVA positions and 25 closed out — a net gain of 61 holders — while 190 added to existing stakes and 154 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $319M. The largest seller was Phoenix Financial, cutting an estimated $141M.
- 533 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2024, up from 481 in Q1 2024.
- Funds reported $9.88B of Teva Pharmaceuticals stock for Q2 2024, up 23% quarter-over-quarter.
- 86 funds opened new Teva Pharmaceuticals positions in Q2 2024 and 25 closed out, a net change of +61 holders.
- The largest Teva Pharmaceuticals buyer in Q2 2024 was Fidelity Investments, an estimated $319M added.
- The largest Teva Pharmaceuticals seller in Q2 2024 was Phoenix Financial, an estimated $141M sold.
Based on aggregated 13F filings for Q2 2024.